Back to Insights and Updates for ProvidersApril 2024

Reminder: trastuzumab biosimilar strategy

Harvard Pilgrim Health Care Commercial  |  Tufts Health Direct  |  Tufts Health Plan Commercial  |  Tufts Health RITogether  |  Tufts Health Together

Point32Health is offering a reminder pertaining to our biosimilar strategy for medical oncology drugs — specifically those in the trastuzumab drug class.

The preferred trastuzumab biosimilars for Harvard Pilgrim Commercial, Tufts Health Plan Commercial, Tufts Health Direct, Tufts Health Together, and Tufts Health RITogether are Kanjinti and Trazimera.

As a reminder, prior authorization is required for all non-preferred trastuzumab products, which include Herceptin, Herceptin Hylecta, Ogivri, Herzuma, and Ontruzant.

For complete details, please refer to the following guidelines:

Audrey Kleinberg,
Director, Provider Relations & Communications

Annmarie Dadoly,
Senior Manager, Provider Communications

Joseph O’Riordan, Susan Panos, Ellen Gustavson, Ryan Francis, Stephen Wong,

Kristin Edmonston,
Production Coordinator

Kristina Cicelova,
Graphic Designer